Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Prostaglandin E2 (compound)


PubChem
Name: Dinoprostone
PubChem Compound ID: 11865423
Description: The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
Molecular formula: C20H31O5-
Molecular weight: 351.457 g/mol
Synonyms:
ZINC03830713; 363-24-6
DrugBank
Identification
Name: Dinoprostone
Name (isomeric): DB00917
Drug Type: small molecule
Description: The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
Synonyms:
PGE2; Dinoprostone Prostaglandin E2; Prostaglandin E2
Brand: Propess, Prostin E2, Prepidil, Cervidil, Prostin E, Prostarmon E
Category: Oxytocics, Prostaglandins
CAS number: 363-24-6
Pharmacology
Indication: For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.
Pharmacology:
Dinoprostone is equivalent to prostaglandin E2 (PGE2). It stimulates labor and delivery by stimulating the uterine, and thus terminates pregnancy. Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the vomiting and/or diarrhea that is not uncommon when dinoproston...
show more »
Mechanism of Action:
Dinoprostone administered intravaginally stimulates the myometrium of the gravid uterus to contract in a manner that is similar to the contractions seen in the term uterus during labor, resulting in the evacuation of the products of conception from the uterus. It is believed that dinoprostone exerts its uterine effects via direct myometrial stimula...
show more »
Absorption: Absorbed at a rate of 0.3 mg per hour over 12 hours while the vaginal system is in place.
Protein binding: 73%, to albumin
Biotransformation: Rapid metabolism of dinoprostone occurs primarily in the local tissues; any systemic absorption of the medication is cleared mainly in the maternal lungs and, secondarily, at sites such as the liver and kidneys.
Route of elimination: The major route of elimination of the products of PGE2 metabolism is the kidneys.
Half Life: Less than 5 minutes.
Toxicity: Oral, mouse: LD50 = 750 mg/kg; Oral, rat: LD50 = 500 mg/kg.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
CarbetocinDinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use.

Targets


Enzymes


Transporters